Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Artisan Mid Cap Fund Matt Kamm, Jason White, Jim Hamel, Angela Wu, Jay Warner | “Twist Bioscience ($TWST) is an advanced life sciences tools company that synthesizes artificial DNA on silicon chips rather than traditional plastic plates, serving researchers in drug discovery, genomics, and agricultural biotechnology. The investment team maintains a bullish long-term thesis on the company as a key enabler of modern biopharma research, though they trimmed the position into recent strength to harvest gains after substantial share-price appreciation. The company's core economic moat is rooted in its proprietary silicon-based synthesis technology, which achieves vastly superior unit economics by drastically miniaturizing chemical reaction volumes. This platform enables Twist to produce high-fidelity synthetic genes and oligonucleotides at a fraction of the cost and time required by legacy chemical synthesis providers. As top-line revenue expanded 23% year-over-year, Twist demonstrated expanding gross margins and favorable operating leverage across its DNA synthesis and protein engineering segments. Near-term catalysts include expanding integration into AI-driven molecular discovery workflows, evidenced by collaborative partnerships with Amazon Bio Discovery and Anthropic to evaluate machine-designed protein binders. Key downside risks include customer budget constraints in academic and clinical biotechnology, potential delays in diagnostic test adoption, and broader capital market volatility impacting biopharma R&D spending.” | BULL | Q3 2026 Oct 14, 2026 | View Pitch |
ACATIS Investment Dr. Hendrik Leber | “Twist Bioscience ($TWST) is a synthetic biology leader that manufactures synthetic genes, oligo pools, and variant libraries by writing DNA on silicon semiconductor chips. Describing the company as the Microsoft of the genetic engineering industry, the manager holds high conviction in Twist's proprietary platform, which fabricates customized synthetic DNA with superior precision, rapid turnaround times, and significant cost savings. The financial mechanics rely on substantial operating leverage derived from high-throughput silicon wafer synthesis, which disrupts expensive legacy 96-well plate chemical methods. The company generates recurring revenue through direct product delivery to biotech innovators alongside high-margin, scalable royalties and milestone partnerships in AI-assisted therapeutic drug discovery. Upcoming catalysts involve continued enterprise uptake of synthetic biology workflows and expansions in AI antibody optimization pipelines. Downside risks include volatile biotechnology venture funding cycles and customer adoption timing for synthetic biology platforms.” | BULL | Q3 2026 Oct 5, 2026 | View Pitch |
Artisan Partners Small Cap Fund Jay Warner | “Twist Bioscience is a life sciences company that leverages a proprietary silicon-based DNA writing platform, with synthetic biology applications across drug discovery, diagnostics, agriculture and industrial materials. Shares rose 116% after the company reported results well ahead of expectations, supported by strength in DNA synthesis and protein solutions, improving demand for next-generation sequencing and guidance calling for continued momentum. Management also reaffirmed its expectation of reaching adjusted EBITDA breakeven in fiscal Q4 2026. Investor enthusiasm increased following the company's analyst day, where management highlighted Twist's current positioning as a beneficiary of AI-enabled drug discovery and growing demand for DNA synthesis and data generation. We trimmed the position following the stock's strong appreciation, consistent with our position-sizing discipline.” | NEUTRAL | Q2 2026 Jul 21, 2026 | View Pitch |
Artisan International Fund Mark L. Yockey | “Twist Bioscience is a life sciences company that leverages a proprietary silicon-based DNA writing platform, with synthetic biology applications across drug discovery, diagnostics, agriculture and ind” | BULL | Q1 2026 Apr 18, 2026 | View Pitch |
Artisan Partners Small Cap Fund Jay Warner | “Twist Bioscience is a life sciences company leveraging a proprietary silicon-based DNA writing platform with synthetic biology applications in drug discovery, diagnostics, agriculture and industrial materials. The company recently reported 18% revenue growth and improved gross margins, driven by strong demand in next-generation sequencing, which helped offset weaker synthetic biology product sales. We view Twist's risk-reward profile as compelling and see the new Veracyte partnership as further validation of its platform, with potential to drive long-term upside. We used the recent pullback as an opportunity to add to our position. BSD Analysis: The manager is bullish on TWST's platform leverage and improving unit economics. With NGS demand strength and strategic partnerships, margin expansion and scale effects can drive a path to profitability.” | BULL | Q3 2025 Oct 20, 2025 | View Pitch |
Conestoga Micro Cap Composite Derek Johnston | “TWST is a rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform that manufactures synthetic DNA by “writing” it on a silicon chip. TWST leverages their unique technology platform to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for NGS sample preparation, and antibody libraries for drug discovery and development. Conestoga was a shareholder of TWST from 2019 to 2020 and sold due to its market cap exceeding our limit. With the weakness in healthcare, Conestoga is reinvesting. TWST's fundamentals have remained robust, management has been upgraded, and we believe they are nearing profitability. BSD Analysis: Twist stands out in synthetic biology with a scalable silicon-based platform enabling advantaged cost structures and expanding gross margins. Revenue growth remains strong across genes, NGS tools, and antibody libraries, supported by diversified end markets in pharma, biotech, and synbio. While EBITDA remains negative, operating leverage is improving, and analysts expect profitability inflection within 12–18 months. Insider ownership is stable, and the balance sheet provides adequate runway. If execution continues, TWST could re-rate meaningfully as investors reward high-growth synthetic biology names approaching profitability.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.